Thalidomide

From WikiMD's WELLNESSPEDIA

(Redirected from Imida-Lab)

Thalidomide is a pharmaceutical drug initially introduced in the 1950s by the German pharmaceutical company Chemie Grünenthal. It was marketed as a mild sleeping aid safe even for pregnant women. However, it was soon discovered that thalidomide caused severe birth defects in thousands of babies born to mothers who had taken the drug during pregnancy. This led to one of the biggest medical scandals and drug recalls in history.

History[edit]

Thalidomide was first marketed in 1957 in Germany under the trade name Contergan. The drug was advertised as a "wonder drug" for insomnia, cough, cold and headache. However, in late 1961, an Australian doctor named William McBride wrote a letter to the editor of The Lancet in which he explained that he had noticed an increase in deformed babies being born at his hospital - all to mothers who had taken thalidomide.

Effects[edit]

Thalidomide causes birth defects by inhibiting angiogenesis, the process through which new blood vessels form from pre-existing vessels. This is a critical process in fetal development. The most common defects observed were phocomelia, a condition in which the long bones in the limbs fail to develop properly, and amelia, a similar condition in which the limbs fail to develop at all.

Current use[edit]

Despite its history, thalidomide is still used today as a treatment for a number of conditions, including multiple myeloma, erythema nodosum leprosum, and in some cases, HIV/AIDS. However, its use is strictly controlled due to its teratogenic effects.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.